MiNK Therapeutics, Inc.INKT

MiNK Therapeutics Inc. is a clinical-stage biotech chasing commercial traction from an allogeneic invariant natural killer T-cell platform whose lead asset, agenT-797, is being tested in multiple indications including acute respiratory distress syndrome and solid tumours. The company does not yet sell a product or turn a profit; it funds operations through equity issuance while burning roughly $1.7 million of cash per quarter and reporting a net loss of $2.7 million for the three months ended 31 March 2026.

Its recent news flow is heavy on platform promise: in May 2026 the company touted “first-in-human” remission data in metastatic testicular cancer and touted clinical evidence from ASGCT 2026 suggesting that a single off-the-shelf iNKT cell product can drive context-dependent immune responses. The company’s website and press materials are studded with product renderings and executive bios that read like a cross between a Big Pharma résumé vault and a cell-therapy brochure, yet the balance sheet remains resolutely pre-revenue: $9.5 million in cash, $10.4 million in total assets, and shareholders’ equity of minus $12.7 million.

Under the bonnet, the 31 March 2026 10-Q shows operating loss of $2.9 million, R&D spend of $1.2 million, and diluted EPS of negative fifty-seven cents on 4.8 million shares. The company’s May 2026 press release calls this “capital-efficient expansion” and touts non-dilutive collaborations as a path to “meaningful commercial revenue potential,” language that is polite for “we still need money and have not yet booked a sale.” The same filing notes that the company’s cash burn is funded by existing cash and equivalents, which stood at $9.5 million on 31 March 2026. Net cash used in operating activities was $1.7 million for the quarter.

The company’s latest SEC submissions confirm that the only concrete dilution in the last reporting window was driven by equity awards to directors and executives, not by financing rounds or product revenues. MiNK’s ownership XML filings for 2-5 June 2026 list director Ryan’s compensation for “services rendered as a member of the MiNK Therapeutics Inc. Board of Directors,” a detail that sits awkwardly beside the image of a lean, cash-generative biotech machine. The company’s SEC company facts JSON confirms these numbers but adds no evidence of near-term revenue, approvals, or commercial launch timelines.

For investors focused on hard metrics, the only numbers that move are the ones you can still count on your fingers: $9.5 million in cash, $12.7 million in negative equity, and a quarterly cash-burn rate that has not slowed since the last filing. The company’s pipeline headlines are real science; the revenue line is still a promise. If you want to see what MiNK actually does today, look at the burn rate and the absence of sales. If you want to see what MiNK hopes to do tomorrow, read the newsroom copy-then treat it as scientific aspiration rather than financial fact.

The company does not disclose guidance, inventory levels, capex, or buybacks in the evidence set, and the 8-K filed on 23 June 2026 relates to the same director compensation item already disclosed in the June ownership XML. In short, the data room is small but transparent: no revenue, no profit, and a cash runway measured in single-digit millions. What the company is not disclosing is more important than what it is: concrete revenue milestones, partner cash infusions, or regulatory approvals remain unproven in the public record.